Ramucirumab + Paclitaxel
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Cancer
Conditions
Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Trial Timeline
Nov 16, 2018 → Dec 1, 2024
NCT ID
NCT03760822About Ramucirumab + Paclitaxel
Ramucirumab + Paclitaxel is a phase 2 stage product being developed by Eli Lilly for Stomach Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03760822. Target conditions include Stomach Cancer, Stomach Neoplasm, Gastric Cancer.
What happened to similar drugs?
1 of 8 similar drugs in Stomach Cancer were approved
Approved (1) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02307812 | Pre-clinical | Completed |
| NCT03762564 | Phase 2 | Completed |
| NCT03760822 | Phase 2 | Active |
| NCT02514551 | Phase 2 | Completed |
Competing Products
20 competing products in Stomach Cancer